|Awarded On||March 29, 2012|
|Title||Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant|
|Program||Product Development Research|
|Award Mechanism||Company Formation|
|Principal Investigator/Program Director||Brenton Scott|
|Cancer Sites||Breast, Leukemia, Lymphoma, Ovary|
Working closely with partners at M. D. Anderson Cancer Center, Texas A&M, and Baylor College of Medicine, Pulmotect is developing a novel, protectable technology to reduce the incidence of pneumonia in immunosuppressed cancer patients and significantly improve how cancer patients are treated. Our therapeutic product, PUL-042, is a combination of two stimulants that boost the lung's own defense mechanisms to create a broad protection against invading pathogens thereby reducing and preventing lung infection. Both cellular and live animal preclinical proof-of-concept experiments have been completed that validate this technology and support moving it forward into the clinic. It is in the most at...